Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Community-Based Study to Determine the Safety and Efficacy of an Extended Course of Alefacept, Following a Standard 12-Week Course of Amevive®, With Commonly Used Clinical Assessment Tools

NCT00168753 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT00168753
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00168753 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Community-Based Study to Determine the Safety and Efficacy of an Extended Course of Alefacept, Following a Standard 12-Week Course of Amevive®, With Commonly Used Clinical Assessment Tools
Lead sponsor
Astellas Pharma Inc
Phase
Phase 4
Overall status
Completed
Start date
July 31, 2004
Completion date
March 31, 2005
Enrollment
114 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

moderate to severe chronic plaque psoriasis